H. Lundbeck 대차 대조표 상태

재무 상태 기준 확인 5/6

H. Lundbeck 의 총 주주 지분은 DKK23.8B 이고 총 부채는 DKK3.7B, 이는 부채 대 자기자본 비율을 15.6% 로 가져옵니다. 총자산과 총부채는 각각 DKK39.5B 및 DKK15.7B 입니다. H. Lundbeck 의 EBIT는 DKK3.4B 이며 이자보상배율은 -27.4 입니다. DKK8.3B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

15.6%

부채 비율

DKK 3.72b

부채

이자 보상 비율	-27.4x
현금	DKK 8.32b
주식	DKK 23.84b
총 부채	DKK 15.68b
총 자산	DKK 39.52b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: LUNA 의 단기 자산 ( DKK17.0B )이 단기 부채( DKK7.8B ).

장기 부채: LUNA 의 단기 자산( DKK17.0B )이 장기 부채( DKK7.9B ).

부채 대 자본 내역 및 분석

부채 수준: LUNA 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: LUNA 의 부채 대 자기자본 비율은 지난 5년간 4.8% 에서 15.6% 로 증가했습니다.

부채 범위: LUNA 의 부채는 영업 현금 흐름 ( 145.8% )에 의해 잘 충당되었습니다.

이자 보장: LUNA 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.

H. Lundbeck 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Less than half of directors are independent

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기